Janssen Pharmaceutical Companies of Johnson and Johnson: Darzalex Faspro (daratumumab and Hyaluronidase-Fihj)-Based Quadruplet Therapy Regimen Shows Significant Improvement in Outcomes for Patients With Transplant-Eligible Newly Diagnosed Multiple Myeloma
December 13, 2023
December 13, 2023
SAN DIEGO, California, Dec. 13 (TNSres) -- The Janssen Pharmaceutical Companies of Johnson and Johnson issued the following news release on Dec. 12, 2023:
* * *
DARZALEX FASPRO(R)-based induction, consolidation and maintenance regimen reduced risk of progression or death by 58 percent compared to standard of care regimen
First presentation of data from Phase 3 PERSEUS study highlighted in late-breaking abstract session at ASH 2023 and simultaneously publish . . .
* * *
DARZALEX FASPRO(R)-based induction, consolidation and maintenance regimen reduced risk of progression or death by 58 percent compared to standard of care regimen
First presentation of data from Phase 3 PERSEUS study highlighted in late-breaking abstract session at ASH 2023 and simultaneously publish . . .